wsd0922-fu
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 20, 2019 (NCT04197934)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07206498 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2025 | Wayshine Biopharm, Inc. |
| NCT06868485 | Phase 2 | Aug 18, 2025 | The Cleveland Clinic, Wayshine Biopharm, Inc. |
| NCT06631989 | Phase 1/Phase 2 (Phase 2) | Aug 21, 2024 | Huazhong University of Science and Technology, Wayshine Biopharm, Inc. |
| NCT04197934 | Phase 1 | Dec 20, 2019 | Food and Drug Administration, Mayo Clinic, National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Wayshine Biopharm, Inc. | For profit | 3 | 3 | 1 | 2024 |
| Food and Drug Administration | Government | 1 | 0 | 1 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2025 |
6 organizations
Page 1 / 1